<?xml version="1.0"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
<channel>
<title>BloggingStocks</title>
<link>http://www.bloggingstocks.com</link>
<description>BloggingStocks</description>
<image>
<url>http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif</url>
<title>BloggingStocks</title>
<link>http://www.bloggingstocks.com</link>
</image>
<language>en-us</language>
<copyright>Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only.</copyright>
<generator>Blogsmith http://www.blogsmith.com/</generator><item><title><![CDATA[Arena Shares Continue to Soar]]></title><link>http://www.bloggingstocks.com/2010/07/26/arena-shares-continue-to-soar/</link><guid isPermaLink="true">http://www.bloggingstocks.com/2010/07/26/arena-shares-continue-to-soar/</guid><comments>http://www.bloggingstocks.com/2010/07/26/arena-shares-continue-to-soar/#comments</comments><description><![CDATA[<p>Filed under: <a href="http://www.bloggingstocks.com/category/stock-picks/" rel="tag">Stock Picks</a></p><img vspace="4" hspace="4" border="1" align="right" alt="" src="http://www.blogcdn.com/www.bloggingstocks.com/media/2008/06/pills.jpg" />Arena Pharmaceuticals (<a href="http://www.dailyfinance.com/quotes/arena-pharmaceuticals-inc/arna/nas">ARNA</a>), which soared over 10% in Monday morning trading, has set a new 52-week high of $6.75. Over the past month, Arena signed a licensing deal for its potential weight-loss drug, lorcaserin, with Japan's Eisai; released study results for the drug; and got a boost from a decision by a Food and Drug Administration panel on rival's Vivus (<a href="http://www.dailyfinance.com/quotes/vivus-inc/vvus/nas" class="inlinked">VVUS</a>) drug. Arena's shares have more than doubled during that time.<br />
<br />
The <a href="http://www.dailyfinance.com/story/company-news/arena-license-weight-loss-drug-to-eisai-in-u-s/19538244/">Eisai licensing deal</a> is potentially worth about $1.3 billion. Meanwhile, the <a href="http://www.dailyfinance.com/story/arena-soars-30-on-results-of-obesity-drug-study/19555929/">study results Arena released</a> showed lorcaserin helped nearly half the patients lose 5% of their weight and improved their chances of keeping it off. Arena's drug did that while exhibiting a safer safety profile than either of its competitors' treatments: Vivus's Qnexa and Orexigen's (<a href="http://www.dailyfinance.com/quotes/orexigen-therapeutics-inc/orex/nas" class="inlinked">OREX</a>) Contrave.<p><a href="http://www.bloggingstocks.com/2010/07/26/arena-shares-continue-to-soar/" rel="bookmark">Continue reading <em>Arena Shares Continue to Soar</em></a></p><p style="padding:5px;background:#ddd;border:1px solid #ccc;clear:both;"><a href="http://www.bloggingstocks.com/2010/07/26/arena-shares-continue-to-soar/">Arena Shares Continue to Soar</a> originally appeared on <a href="http://www.bloggingstocks.com">BloggingStocks</a> on Mon, 26 Jul 2010 14:30:00 EST.  Please see our <a href="http://www.weblogsinc.com/feed-terms/">terms for use of feeds</a>.</p><h6 style="clear: both; padding: 8px 0 0 0; height: 2px; font-size: 1px; border: 0; margin: 0; padding: 0;"></h6><a href="http://www.bloggingstocks.com/2010/07/26/arena-shares-continue-to-soar/" rel="bookmark" title="Permanent link to this entry">Permalink</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/forward/19568527/" title="Send this entry to a friend via email">Email this</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/2010/07/26/arena-shares-continue-to-soar/#comments" title="View reader comments on this entry">Comments</a>]]></description><category>arena</category><category>arna</category><category>Contrave</category><category>inthenews</category><category>lorcaserin</category><category>obesity</category><category>obesity drugs</category><category>orex</category><category>orexigen</category><category>Qnexa</category><category>vivus</category><category>vvus</category><category>weight loss</category><category>weight loss drugs</category><dc:creator><![CDATA[Melly Alazraki]]></dc:creator><pubDate>Mon, 26 Jul 2010 14:30:00 EST</pubDate></item><item><title><![CDATA[Vivus Looks Very Interesting After Falling More Than 50%]]></title><link>http://www.bloggingstocks.com/2010/07/16/vivus-looks-very-interesting-after-falling-more-than-50/</link><guid isPermaLink="true">http://www.bloggingstocks.com/2010/07/16/vivus-looks-very-interesting-after-falling-more-than-50/</guid><comments>http://www.bloggingstocks.com/2010/07/16/vivus-looks-very-interesting-after-falling-more-than-50/#comments</comments><description><![CDATA[<p>Filed under: <a href="http://www.bloggingstocks.com/category/stocks-to-buy/" rel="tag">Stocks to Buy</a></p><img vspace="4" hspace="4" border="1" align="right" src="http://www.blogcdn.com/www.bloggingstocks.com/media/2008/02/pill-bottle-at244-by-shutr.jpg"  alt="" />On Thursday afternoon after the close of the New York York Stock Exchange, a FDA panel voted 10 to 6 against recommending Vivus'(<a href="http://www.dailyfinance.com/quotes/vivus-inc/vvus/nas">VVUS</a>) weight loss drug Qnexa for approval. Apparently there was concern that the data supporting Qnexa wasn't strong enough for a drug that could be used by millions for an indefinite time period.<br />
<br />
The FDA does not have to act in accordance with the panel's recommendation, although the agency rarely fails to do so. Chief Executive Leland Wilson said the panel vote is "a recommendation and not a final step in the drug-approval process," and that his company would work with the FDA "to address the labeling and safety questions raised during today's proceedings." A final decision is expected in October.<br />
<br />
The data that the company presented to the FDA was based on one year, but a company spokesperson said that two-year data will be available by September, so there is definitely still hope for this drug.<br />
<br />
"I don't think that Qnexa is dead, but it has to be heavily discounted [from the stock price] until we hear from the FDA," said Rodman &amp; Renshaw analyst Elemer Piros.<br />
<br />
According to Lazard analyst William Tanner, "Should Vivus be required to conduct a new trial to generate additional safety data for its low and mid doses, final approval and launch could be delayed by as much as two years."<br />
<br />
<span class="Apple-style-span" style="border-collapse: separate; color: rgb(0, 0, 0); font-family: Verdana,sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; font-size: medium;"><span class="Apple-style-span" style="color: rgb(68, 68, 68); font-family: verdana,arial,sans-serif; font-size: 13px; line-height: 19px; text-align: left;"><br />
</span></span><p><a href="http://www.bloggingstocks.com/2010/07/16/vivus-looks-very-interesting-after-falling-more-than-50/" rel="bookmark">Continue reading <em>Vivus Looks Very Interesting After Falling More Than 50%</em></a></p><p style="padding:5px;background:#ddd;border:1px solid #ccc;clear:both;"><a href="http://www.bloggingstocks.com/2010/07/16/vivus-looks-very-interesting-after-falling-more-than-50/">Vivus Looks Very Interesting After Falling More Than 50%</a> originally appeared on <a href="http://www.bloggingstocks.com">BloggingStocks</a> on Fri, 16 Jul 2010 14:50:00 EST.  Please see our <a href="http://www.weblogsinc.com/feed-terms/">terms for use of feeds</a>.</p><h6 style="clear: both; padding: 8px 0 0 0; height: 2px; font-size: 1px; border: 0; margin: 0; padding: 0;"></h6><a href="http://www.bloggingstocks.com/2010/07/16/vivus-looks-very-interesting-after-falling-more-than-50/" rel="bookmark" title="Permanent link to this entry">Permalink</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/forward/19557704/" title="Send this entry to a friend via email">Email this</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/2010/07/16/vivus-looks-very-interesting-after-falling-more-than-50/#comments" title="View reader comments on this entry">Comments</a>]]></description><category>inthenews</category><category>Qnexa</category><category>Stocks to buy</category><category>vvus</category><dc:creator><![CDATA[Jason Raznick]]></dc:creator><pubDate>Fri, 16 Jul 2010 14:50:00 EST</pubDate></item><item><title><![CDATA[Closing Bell: The never ending rally (ABX, GE, PALM, VVUS)]]></title><link>http://www.bloggingstocks.com/2009/09/09/closing-bell-the-never-ending-rally-abx-ge-palm-vvus/</link><guid isPermaLink="true">http://www.bloggingstocks.com/2009/09/09/closing-bell-the-never-ending-rally-abx-ge-palm-vvus/</guid><comments>http://www.bloggingstocks.com/2009/09/09/closing-bell-the-never-ending-rally-abx-ge-palm-vvus/#comments</comments><description><![CDATA[<p>Filed under: <a href="http://www.bloggingstocks.com/category/ge/" rel="tag">General Electric (GE)</a>, <a href="http://www.bloggingstocks.com/category/abx/" rel="tag">Barrick Gold (ABX)</a>, <a href="http://www.bloggingstocks.com/category/palm/" rel="tag">Palm Inc (PALM)</a></p><img vspace="4" hspace="4" border="1" align="right" alt="" src="http://www.blogcdn.com/www.bloggingstocks.com/media/2007/08/bell-green.jpg" />Today was another up and away day, although after the 2:00 PM Beige Book and after a Treasury auction, it felt like today was just going to be a difficult one to call. <br /><br />This is a light week on data and a light day on earnings and that makes it a hard tell each day to have serious conviction for bulls and bears alike. The DJIA went above 9,500 and marks the 4th day in a row of a rally. <br /><br />Here are today's unofficial closing bell levels:<br /><br />Dow 	9,538.23 	+40.89 	(0.43%) <br />S&amp;P 500 	1,032.47 	+7.08 	(0.69%) <br />Nasdaq 	2,058.60 	+20.83 	(1.02%)<br /><br /><a href="http://247wallst.com/2009/09/09/top-analyst-upgrades-cof-ebay-gs-jblu-ltm-ma-sndk-ups-wynn/">Top Analyst Upgrades</a><br /><a href="http://247wallst.com/2009/09/09/top-analyst-downgrades-ccj-chkp-dish-dd-kft-mhp-palm-rosg-ubs/">Top Analyst Downgrades</a><br /><a href="http://247wallst.com/2009/09/09/top-day-trader-alerts-ge-palm-vvus-orex-arna-mnkd/">Top Day Trader Alert Stocks</a><a href="http://finance.aol.com/quotes/barrick-gold-corporation/abx/nys"><br /></a><p><a href="http://www.bloggingstocks.com/2009/09/09/closing-bell-the-never-ending-rally-abx-ge-palm-vvus/" rel="bookmark">Continue reading <em>Closing Bell: The never ending rally (ABX, GE, PALM, VVUS)</em></a></p><p style="padding:5px;background:#ddd;border:1px solid #ccc;clear:both;"><a href="http://www.bloggingstocks.com/2009/09/09/closing-bell-the-never-ending-rally-abx-ge-palm-vvus/">Closing Bell: The never ending rally (ABX, GE, PALM, VVUS)</a> originally appeared on <a href="http://www.bloggingstocks.com">BloggingStocks</a> on Wed, 09 Sep 2009 16:00:00 EST.  Please see our <a href="http://www.weblogsinc.com/feed-terms/">terms for use of feeds</a>.</p><h6 style="clear: both; padding: 8px 0 0 0; height: 2px; font-size: 1px; border: 0; margin: 0; padding: 0;"></h6><a href="http://www.bloggingstocks.com/2009/09/09/closing-bell-the-never-ending-rally-abx-ge-palm-vvus/" rel="bookmark" title="Permanent link to this entry">Permalink</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/forward/19156016/" title="Send this entry to a friend via email">Email this</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/2009/09/09/closing-bell-the-never-ending-rally-abx-ge-palm-vvus/#comments" title="View reader comments on this entry">Comments</a>]]></description><category>beige book</category><category>BeigeBook</category><category>featured</category><category>qnexa</category><category>treasury</category><category>VVUS</category><dc:creator><![CDATA[Jon Ogg]]></dc:creator><pubDate>Wed, 09 Sep 2009 16:00:00 EST</pubDate></item></channel></rss>
